March 19, 20260 citationsOpen Access
Ver artículo completoActivated Clotting Time Platforms Matter: Evidence Gaps and Real-World Variability in Anticoagulation Targets During Left Atrial Ablation.
Resultado clave
Activated clotting time platforms yield simultaneously measured values differing by 50-60 seconds (a 15-25% discrepancy), challenging universal targets and driving variable heparin dosing.
Puntos clave
- The aim is to evaluate differences in activated clotting time (ACT) values across various measurement platforms and how these affect anticoagulation strategies in practice.
- Conducted a systematic review of studies comparing ACT measurement across platforms during left atrial ablation.
- Executed an international survey of physicians on their use of ACT platforms and heparin dosing practices.
- Collected data on ACT targets and the platforms used by electrophysiologists.
- Actively measured ACT values showed substantial discrepancies among platforms, with mean differences of 50-60 seconds.
- A 15-25% discrepancy was noted at ACT targets of 300-350 seconds among different platforms.
- Survey responses highlighted variability in ACT target ranges and heparin dosing strategies based on the platform used.
PICO estructurado
Do measured ACT values differ across measurement platforms during left atrial ablation?
P
Población
4 electrophysiology-specific studies comparing ACT platforms and 164 electrophysiologists (82% Europe, 13% North America)
I
Intervención
Different ACT measurement platforms (Hemochron, Medtronic ACT Plus, Abbott i-STAT)
C
Comparador
Direct comparison between ACT platforms
O
Resultado
Differences in measured ACT values across platforms and variability in anticoagulation strategiessurrogate
Substantial differences exist between ACT platforms, challenging the assumption of universal ACT targets and highlighting the need for platform-specific interpretation during left atrial ablation.
Resultado numérico
Tasa de eventos absoluta: 0% vs 0%
Resumen
Background Activated clotting time (ACT) is used to guide intraprocedural heparin anticoagulation during left atrial ablation, with guideline-recommended target values generally assumed to be device-independent.Objective To assess whether measured ACT values differ across measurement platforms and whether contemporary anticoagulation strategies vary accordingly in clinical practice.Methods We performed a PRISMA-registered systematic review of studies directly comparing ACT values across different measurement platforms during left atrial ablation. In parallel, we conducted an international physician survey assessing ACT platforms, heparin dosing strategies and targeted ACT ranges.Results The systematic review identified four electrophysiology-specific studies comparing ACT platforms. Across all studies, simultaneously measured ACT values differed substantially between platforms, with mean paired differences of 50-60 seconds, corresponding to a 15-25% discrepancy at ACT targets of 300-350 s. These inter-platform differences persisted despite high correlation between devices. The survey was completed by 164 electrophysiologists (82% Europe, 13% North America). The most commonly used platforms were Hemochron (42%), Medtronic ACT Plus (27%), and Abbott i-STAT (16%). Target ACT ranges and heparin dosing strategies varied by platform: higher ACT targets and higher weight-based heparin doses were most frequently reported with Hemochron, lower targets and doses were more common with i-STAT; Medtronic users showed an intermediate pattern. Nearly one-third of respondents reported modifying heparin dosing after switching ACT platforms.Conclusion Available cross-validation data demonstrate substantial differences between ACT platforms. Real-world heparin administration strategies and ACT targets vary markedly by platform. These findings challenge the assumption of universal ACT targets and highlight the need for platform-specific interpretation.